This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Mcgill University, The Hospital for Sick Children. Active years: 2021-2023.
Location History:
- Toronto, CA (2021)
- Mississauga, CA (2023)
Company Filing History:
2 out of 570 
2 out of 167 
Years Active: 2021-2023
Title: Innovations of Perrin Baker in Biofilm Research
Introduction
Perrin Baker is an accomplished inventor based in Toronto, Canada. He has made significant contributions to the field of biofilm research, particularly in the development of methods to inhibit and disperse biofilms. With a total of 2 patents, his work has the potential to impact medical and non-medical applications significantly.
Latest Patents
Baker's latest patents focus on soluble bacterial and fungal proteins and their methods and uses in inhibiting and dispersing biofilm. The present disclosure relates to methods of treating or preventing biofilm-related infections and preventing biofilm formation on indwelling medical devices, implants, and non-medical surfaces. This involves administering at least one soluble microbial protein encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The disclosure further provides particular soluble glycosyl hydrolases and compositions thereof.
Career Highlights
Throughout his career, Perrin Baker has worked with prestigious institutions such as McGill University and The Hospital for Sick Children. His research has focused on innovative solutions to complex biological problems, particularly in the context of biofilm management.
Collaborations
Baker has collaborated with notable colleagues, including Dustin Little and Lynne P. Howell. These collaborations have enriched his research and contributed to the advancement of knowledge in his field.
Conclusion
Perrin Baker's innovative work in biofilm research showcases his dedication to improving medical and non-medical applications through scientific advancements. His patents reflect a commitment to addressing critical challenges in biofilm management.